We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Treatment of Soft-Tissue Sarcoma by Chemotherapy

Edward T. Krementz, MD; James O. Shaver, MD
JAMA. 1963;184(2):149-152. doi:10.1001/jama.1963.73700150017022b.
Text Size: A A A
Published online


THE TREATMENT of soft-tissue sarcomas with chemotherapeutic agents has been in progress for over 20 yr. The first effective agent, mechlorethamine hydrochloride (HN2), originally used during World War II, was reported by Gilman and Phillips in 1946.1 These and other observers noted that lymphomas and leukemias often regressed dramatically in response to mechlorethamine hydrochloride, but only about one of ten of the solid cancers responded. In all patients objective improvement was short-lived. In recent years several new agents have been developed which are more effective than mechlorethamine hydrochloride. Among them, meractinomycin has proved useful in the treatment of childhood sarcomas and renal carcinomas2; fluorouracil and idoxuridine in adenocarcinoma of the breast and gastrointestinal tract3; methotrexate in choriocarcinoma of the female4; and vinblastine sulfate in Hodgkin's sarcoma resistant to other chemotherapeutic agents.5

Special techniques have been introduced which have made chemotherapy more effective. Administration


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.